These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 34146705)

  • 1. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
    Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
    Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation.
    Li R; Huang X; Shen L; Zhang T; Liu N; Hou X; Wong G
    Cell Mol Life Sci; 2024 Aug; 81(1):377. PubMed ID: 39212733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia.
    Miller RL; Dhavale DD; O'Shea JY; Andruska KM; Liu J; Franklin EE; Buddhala C; Loftin SK; Cirrito JR; Perrin RJ; Cairns NJ; Campbell MC; Perlmutter JS; Kotzbauer PT
    Ann Clin Transl Neurol; 2022 Feb; 9(2):106-121. PubMed ID: 35060360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.
    Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J
    Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
    Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
    Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.
    Mandal PK; Pettegrew JW; Masliah E; Hamilton RL; Mandal R
    Neurochem Res; 2006 Sep; 31(9):1153-62. PubMed ID: 16947080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology.
    Bassil F; Brown HJ; Pattabhiraman S; Iwasyk JE; Maghames CM; Meymand ES; Cox TO; Riddle DM; Zhang B; Trojanowski JQ; Lee VM
    Neuron; 2020 Jan; 105(2):260-275.e6. PubMed ID: 31759806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.
    Tsigelny IF; Crews L; Desplats P; Shaked GM; Sharikov Y; Mizuno H; Spencer B; Rockenstein E; Trejo M; Platoshyn O; Yuan JX; Masliah E
    PLoS One; 2008 Sep; 3(9):e3135. PubMed ID: 18769546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model.
    Lloyd GM; Dhillon JS; Gorion KM; Riffe C; Fromholt SE; Xia Y; Giasson BI; Borchelt DR
    Mol Neurodegener; 2021 Sep; 16(1):63. PubMed ID: 34503546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease.
    Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS
    Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
    Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
    Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
    Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
    Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
    Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.